These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 24781224)

  • 21. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.
    Kane JM; Crandall DT; Marcus RN; Eudicone J; Pikalov A; Carson WH; Swyzen W
    Schizophr Res; 2007 Sep; 95(1-3):143-50. PubMed ID: 17644313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of aripiprazole in early onset schizophrenia: safety and efficacy.
    Normala I; Hamidin A
    Med J Malaysia; 2009 Sep; 64(3):240-1. PubMed ID: 20527278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extrapyramidal side effects associated with aripiprazole administration in a schizophrenic patient.
    Hung GC; Chen YY
    Pharmacopsychiatry; 2007 Mar; 40(2):83-4. PubMed ID: 17447180
    [No Abstract]   [Full Text] [Related]  

  • 25. Torticollis after low-dose aripiprazole administration in a Thai schizophrenia patient.
    Ittasakul P; Srivastava S; Hiranyatheb T; Ketter TA
    Asian J Psychiatr; 2012 Dec; 5(4):365-6. PubMed ID: 23174451
    [No Abstract]   [Full Text] [Related]  

  • 26. Aripiprazole-related body-weight gain and nutritional counseling.
    Hou YC; Lai CH
    J Neuropsychiatry Clin Neurosci; 2011; 23(2):E44-5. PubMed ID: 21677226
    [No Abstract]   [Full Text] [Related]  

  • 27. Improvement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literature.
    Ono S; Suzuki Y; Shindo M; Endo T; Fukui N; Sugai T; Someya T
    J Clin Pharm Ther; 2012 Jun; 37(3):370-2. PubMed ID: 22023382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.
    Takeuchi H; Suzuki T; Uchida H; Nakajima S; Nomura K; Kikuchi T; Manki H; Watanabe K; Kashima H
    J Clin Psychopharmacol; 2008 Oct; 28(5):540-3. PubMed ID: 18794650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aripiprazole: a review of its pharmacology and clinical use.
    Taylor DM
    Int J Clin Pract; 2003; 57(1):49-54. PubMed ID: 12587943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole.
    Lian J; Huang XF; Pai N; Deng C
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1157-8; author reply 1159. PubMed ID: 20381569
    [No Abstract]   [Full Text] [Related]  

  • 31. Aripiprazole in schizophrenia: consensus guidelines.
    Travis MJ; Burns T; Dursun S; Fahy T; Frangou S; Gray R; Haddad PM; Hunter R; Taylor DM; Young AH
    Int J Clin Pract; 2005 Apr; 59(4):485-95. PubMed ID: 15853869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
    Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
    Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High dosage of aripiprazole-induced dysphagia.
    Lin TW; Lee BS; Liao YC; Chiu NY; Hsu WY
    Int J Eat Disord; 2012 Mar; 45(2):305-6. PubMed ID: 21541978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan].
    Ishigooka J; Noda T; Nishiyama K; Tamaru N; Shima T; Yamasaki Y; Tadori Y
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2016 Jun; 36(3):63-8. PubMed ID: 27506082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of the safety and tolerability of aripiprazole.
    Pae CU
    Expert Opin Drug Saf; 2009 May; 8(3):373-86. PubMed ID: 19505266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical use of aripiprazole in patients with schizophrenia: a real-life setting results from the German Postmarketing Surveillance Study.
    Messer T; Schmauss M; Spevakne-Goeroecs T; Kungel M; Ebrecht M; Werner C; Modell S
    World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):231-8. PubMed ID: 20218786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching of antipsychotics to aripiprazole in the treatment of schizophrenia.
    Lin HC; Chong MY; Lee Y; Yeh WC; Lin PY
    Chang Gung Med J; 2009; 32(4):409-16. PubMed ID: 19664347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee JH; Lee YH; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2009; 32(5):243-9. PubMed ID: 19620849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination loxapine and aripiprazole for refractory hallucinations in schizophrenia.
    Sokolski KN
    Ann Pharmacother; 2011 Jul; 45(7-8):e36. PubMed ID: 21672885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism.
    Naber D; Lambert M
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1213-9. PubMed ID: 15588748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.